Cargando…

Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes

Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore, it is necessary to consider adverse reactions of the drug at high doses as well as at lower doses after the indic...

Descripción completa

Detalles Bibliográficos
Autor principal: Seo, Young-Gyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for the Study of Obesity 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017323/
https://www.ncbi.nlm.nih.gov/pubmed/33071241
http://dx.doi.org/10.7570/jomes20059
_version_ 1783674041801900032
author Seo, Young-Gyun
author_facet Seo, Young-Gyun
author_sort Seo, Young-Gyun
collection PubMed
description Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore, it is necessary to consider adverse reactions of the drug at high doses as well as at lower doses after the indication has been expanded. Body mass index criteria for patients prescribed the drug in the real world tend to be applied less rigorously, which may increase the number of adverse reactions due to over-prescription. Liraglutide treatment was found effective and safe in some studies, while others have warned about its risks. Therefore, this review summarizes the current data available on side effects associated with liraglutide.
format Online
Article
Text
id pubmed-8017323
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean Society for the Study of Obesity
record_format MEDLINE/PubMed
spelling pubmed-80173232021-04-02 Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes Seo, Young-Gyun J Obes Metab Syndr Review Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore, it is necessary to consider adverse reactions of the drug at high doses as well as at lower doses after the indication has been expanded. Body mass index criteria for patients prescribed the drug in the real world tend to be applied less rigorously, which may increase the number of adverse reactions due to over-prescription. Liraglutide treatment was found effective and safe in some studies, while others have warned about its risks. Therefore, this review summarizes the current data available on side effects associated with liraglutide. Korean Society for the Study of Obesity 2021-03-30 2020-10-19 /pmc/articles/PMC8017323/ /pubmed/33071241 http://dx.doi.org/10.7570/jomes20059 Text en Copyright © 2021 Korean Society for the Study of Obesity This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Seo, Young-Gyun
Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
title Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
title_full Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
title_fullStr Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
title_full_unstemmed Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
title_short Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
title_sort side effects associated with liraglutide treatment for obesity as well as diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017323/
https://www.ncbi.nlm.nih.gov/pubmed/33071241
http://dx.doi.org/10.7570/jomes20059
work_keys_str_mv AT seoyounggyun sideeffectsassociatedwithliraglutidetreatmentforobesityaswellasdiabetes